Total raised
—
Last: Seed 2017-11
Stage
Seed
Founded
2017
Headcount
6
HQ
Yokne'am Illit
Sector
Health Tech & Life Sciences
About
Touch Brain has developed novel formulations of existing drugs that result in unique activity for the treatment of large-market central nervous system diseases. Touch Brain's technology is based on proprietary formulations for intranasal administration and novel combinations of approved drugs. The intranasal route holds many advantages including increased bio-availability, elimination of first-pass metabolism, improvement of brain targeting, convenience, and patient compliance.
Funding history · 1 round · — total
2017-11
Seed
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
parkinsonmedical-technologiespharmaceuticalstreatments